profit from every $100 of sales.
$0$100
Cognition Therapeutics
$0.68+0.52% today
-55.9% in 1 year
1-year low $0.601-year high $1.80
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cognition Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$23.5 million of profit last year.
SalesProfit
Cognition Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cognition Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Cognition Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -21 | -26 | -34 | -24 | |
| -21 | -26 | -34 | -23 | |
| -21 | -26 | -34 | -23 | |
| -0.91 | -0.86 | -0.86 | -0.32 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 50 | 35 | 30 | 48 |
| Cash | 42 | 30 | 25 | 37 |
| Total debt | 1 | 1 | 1 | 1 |
| Total liabilities | 10 | 11 | 11 | 14 |
| 40 | 24 | 19 | 34 | |
| 24 | 30 | 40 | 73 | |
| -40.5% | -79.2% | -137.1% | -53.1% | |
| -53.2% | -105.4% | -181.2% | -68.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -16 | -28 | -25 | |
| 0 | 0 | 0 | – | |
| -19 | -16 | -28 | -25 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 4 | 4 | 2 |
Valuation
- –
- –
- –
- 3.6×
- –
- –
- –
- -38.0%
- -36.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -141.9%
- -72.5%
- -55.7%
- -41.5%
- -142.4%
- –
Growth
- –
- –
- +13.7%
- –
- +34.5%
Financial health
- 0.9×
- 0.01
- 0.7%
- -14,280.3×
- 5.92
- 5.92
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
Bottom 1%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.05 | -0.06 | +16.7% |
| Mar 26, 2026 | -0.02 | -0.06 | +66.7% |
| Nov 6, 2025 | -0.06 | -0.07 | +14.3% |
| Aug 7, 2025 | -0.11 | -0.12 | +8.3% |
| May 7, 2025 | -0.14 | -0.12 | −16.7% |
| Mar 20, 2025 | -0.17 | -0.16 | −6.3% |
| Nov 13, 2024 | -0.25 | -0.24 | −4.2% |
| Aug 8, 2024 | -0.18 | -0.22 | +18.2% |
News
Cognition outlines mid-2027 Phase III start in DLB and cash runway into Q4 2027Seeking Alpha · Nov 6, 2026Cognition Therapeutics, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 5, 2026Honeywell Technologies Launches Forge Plant Cognition with Dangote, Built with NVIDIA AI and Dell Technologies CapabilitiesYahoo Finance · Oct 26, 2026Honeywell (HON) Unveils Forge Cognition To Bring AI Into Facility OperationsYahoo Finance · Oct 23, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
40No pass
Philip Fisher
33No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
30No pass
Questions about Cognition Therapeutics
Is Cognition Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cognition Therapeutics AI analysis
What does Cognition Therapeutics do?
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. It is in Biotechnology.
Does Cognition Therapeutics pay a dividend?
No. Cognition Therapeutics does not pay a dividend at the moment.
Is Cognition Therapeutics stock halal?
No. Cognition Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 57% of its market value, at or above the 33% limit. How we check
How has Cognition Therapeutics stock done over the past year?
Down 55.9% over the past twelve months, to $0.68. It traded between $0.60 and $1.80 and is 62.2% below its high.
Who are Cognition Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Cognition Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.